爱尔兰爵士制药去纤苷治疗肝小静脉闭塞病效果如何？

(Defibrotide) is a new drug developed abroad to prevent and treat thrombotic diseases. Defibrinoside not only has anti-thrombotic and fibrinolytic effects, but can also protect and improve cardiac function after myocardial infarction without toxic effects. In recent years, Irish Jazz Pharmaceuticals' defibrotide has been tried abroad for the clinical prevention and treatment of various thrombotic diseases, and promising results have been achieved. So, how effective is Sir Irish Pharmaceuticals' defibrotide in treating hepatic veno-occlusive disease?

Gentium has announced the results of a clinical trial of defibrotide for the treatment of hepatic veno-occlusive disease. The study was a historically controlled, multi-center, open-label phase III clinical trial, with the purpose of evaluating the safety and effectiveness of 25 mg/kg/day. The results showed that the patient group treated with Sir Irish Pharmaceuticals' defibrotide had a trend towards complete remission and survival, but the primary and secondary endpoints of the trial did not reach the significance level set by the study at 100 days. As for safety: there were no differences in adverse events between the historical control and treatment groups.

A European research group (including 19 treatment centers) reported the efficacy of defibrotide in 40 patients with hepatic veno-occlusive disease, 28 of whom were patients with severe hepatic veno-occlusive disease or multiple organ failure. The dosage of defibrotide is 10~40 mg/kg/d, the median application time is 18 days, and the median time of starting medication is +14 (-2+53) days after transplantation. The results showed that 22 cases (55%) had complete remission, and 17 cases (43%) survived +100 days.

Jazz Pharmaceuticals was founded in 2003 and is headquartered in Dublin, Ireland, with 885 full-time employees. It is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of pharmaceutical products. Its drugs are quite effective in treating hepatic veno-occlusive disease, and patients can use them with confidence.

Recommended hot articles: /newsDetail/87150.html